Old Paradoxes and New Opportunities for Appetite Control in Obesity

Trends Endocrinol Metab. 2021 May;32(5):264-294. doi: 10.1016/j.tem.2021.02.005. Epub 2021 Mar 8.

Abstract

Human obesity is accompanied by alterations in the blood concentrations of multiple circulating appetite regulators. Paradoxically, most of the appetite-inhibitory hormones are elevated in nonsyndromic obesity, while most of the appetite stimulatory hormones are reduced, perhaps reflecting vain attempts of regulation by inefficient feedback circuitries. In this context, it is important to understand which appetite regulators exhibit a convergent rather than paradoxical behavior and hence are likely to contribute to the maintenance of the obese state. Pharmacological interventions in obesity should preferentially consist of the supplementation of deficient appetite inhibitors or the neutralization of excessive appetite stimulators. Here, we critically analyze the current literature on appetite-regulatory peptide hormones. We propose a short-list of appetite modulators that may constitute the best candidates for therapeutic interventions.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Appetite Regulation* / drug effects
  • Dietary Supplements
  • Hormones
  • Humans
  • Obesity* / therapy

Substances

  • Hormones